Gary Whale
Net worth: 199 258 $ as of 31/05/2026
Net worth: 199 258 $ as of 31/05/2026
Gary Whale is currently Chief Technology Officer at Zura Bio Ltd. since 2023.
Formerly, Dr. Whale was Vice President & Global Head-Technical Operations at Recordati UK Ltd. from 2020 to 2022 and Chief Operating Officer at VHsquared Ltd. from 2018 to 2020.
Education includes undergraduate and graduate degrees from the University of London and a doctorate from The Robert Gordon University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/04/2026 | 46,339 ( 0.05% ) | 199 258 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| ZURA BIO LIMITED | Chief Tech/Sci/R&D Officer | 01/03/2023 |
| Companies | Position | End |
|---|---|---|
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services Supplies medicines and medical devices | Chief Tech/Sci/R&D Officer | 01/01/2022 |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Chief Operating Officer | 01/04/2020 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Robert Gordon University
The Robert Gordon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Health Technology |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services Supplies medicines and medical devices | Distribution Services |
Zura Bio Ltd.
Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Select your edition
All financial news and data tailored to specific country editions